dapagliflozin vs semaglutide SURPASS-2 (NEJM 2021) was the definitive head-to-head: tirzepatide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Comparative Cardiovascular Effectiveness of Glucagon-Like
Pay in 4 interest-free payments of $7.33 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7




























